PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On September 5, 2017, Shing-Yin (Helen) Tsui, the senior vice president, finance, secretary and principal accounting officer of PhaseRx, Inc. (the “Company”), notified the Company of her resignation from all positions with the Company, effective as of September 15, 2017. Upon effectiveness of Ms. Tsui’s resignation, Robert W. Overell, the Company’s president and chief executive officer, will replace Ms. Tsui as the secretary of the Company.
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle. PhaseRx, Inc. (NASDAQ:PZRX) Recent Trading Information
PhaseRx, Inc. (NASDAQ:PZRX) closed its last trading session down -0.001 at 0.570 with 10,894 shares trading hands.